Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432

Journal of Pharmacology and Experimental Therapeutics

Volumn 351, Issue 3, 2014, Pages 628-641

  Lord, Brian ^a   Aluisio, Leah ^a   Shoblock, James R ^a   Neff, Robert A ^a   Varlinskaya, Elena I ^b   Ceusters, Marc ^a   Lovenberg, Timothy W ^a   Carruthers, Nicholas ^a   Bonaventure, Pascal ^a   Letavic, Michael A ^a   Deak, Terrence ^b   Drinkenburg, Wilhelmus ^a   Bhattacharya, Anindya ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b BINGHAMTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL N [[1 (4 PHENYLPIPERAZIN 1 YL)CYCLOHEXYL]METHYL] 1,2,3,4 TETRAHYDROISOQUINOLINE 5 CARBOXAMIDE; ADENOSINE DERIVATIVE; AMPHETAMINE; INTERLEUKIN 1BETA; PURINERGIC P2X RECEPTOR ANTAGONIST; PURINERGIC P2X7 RECEPTOR; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; [2' (3') O (4 BENZOYLBENZOYL)ADENOSINE 5' TRIPHOSPHATE TRI(TRIETHYLAMMONIUM)]; CENTRAL NERVOUS SYSTEM AGENTS;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DEPRESSION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ELECTROENCEPHALOGRAPHY; EXPERIMENTAL HYPERACTIVITY; FOOTSHOCK; HUMAN; IN VIVO STUDY; MALE; MANIA; MOUSE; NONHUMAN; PAIN; PLASMA CLEARANCE; RAT; SOCIAL BEHAVIOR; SOCIAL INTERACTION; SOCIAL PREFERENCE; STRESS; ANIMAL; DOSE RESPONSE; METABOLISM; NEURALGIA; NEWBORN; SPRAGUE DAWLEY RAT;

ANIMALS; ANIMALS, NEWBORN; CENTRAL NERVOUS SYSTEM AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MICE; NEURALGIA; PURINERGIC P2X RECEPTOR ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PURINERGIC P2X7;

EID: 84908409069     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.218487     Document Type: Article

References (46)

1. Abbracchio MP, Burnstock G, Verkhratsky A, and Zimmermann H (2009) Purinergic signalling in the nervous system: an overview. Trends Neurosci 32:19-29.
2. Alves LA, Bezerra RJ, Faria RX, Ferreira LG, and da Silva Frutuoso V (2013) Physiological roles and potential therapeutic applications of the P2X7 receptor in inflammation and pain. Molecules 18:10953-10972.
3. Andó RD and Sperlágh B (2013) The role of glutamate release mediated by extrasynaptic P2X7 receptors in animal models of neuropathic pain. Brain Res Bull 93:80-85.
4. Arakawa H, Blandino P, Jr, and Deak T (2009) Central infusion of interleukin-1 receptor antagonist blocks the reduction in social behavior produced by prior stressor exposure. Physiol Behav 98:139-146.
5. Arakawa H, Cruz S, and Deak T (2011) From models to mechanisms: odorant communication as a key determinant of social behavior in rodents during illness-associated states. Neurosci Biobehav Rev 35:1916-1928.
6. Babiloni C, Infarinato F, Aujard F, Bastlund JF, Bentivoglio M, Bertini G, Del Percio C, Fabene PF, Forloni G, and Herrero Ezquerro MT, et al. (2013) Effects of pharmacological agents, sleep deprivation, hypoxia and transcranial magnetic stimulation on electroencephalographic rhythms in rodents: towards translational challenge models for drug discovery in Alzheimer's disease. Clin Neurophysiol 124:437-451.
7. Backlund L, Nikamo P, Hukic DS, Ek IR, Träskman-Bendz L, Landén M, Edman G, Schalling M, Frisén L, and Osby U (2011) Cognitive manic symptoms associated with the P2RX7 gene in bipolar disorder. Bipolar Disord 13:500-508.
8. Barbier AJ, Aluisio L, Lord B, Qu Y, Wilson SJ, Boggs JD, Bonaventure P, Miller K, Fraser I, and Dvorak L, et al. (2007) Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor. Eur J Pharmacol 576:43-54.
9. Bennett MR (2007) Synaptic P2X7 receptor regenerative-loop hypothesis for depression. Aust N Z J Psychiatry 41:563-571.
10. Bhattacharya A, Neff RA, and Wickenden AD (2011) The physiology, pharmacology and future of P2X7 as an analgesic drug target: hype or promise? Curr Pharm Biotechnol 12:1698-1706.
11. Bhattacharya A, Wang Q, Ao H, Shoblock JR, Lord B, Aluisio L, Fraser I, Nepomuceno D, Neff RA, and Welty N, et al. (2013) Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. Br J Pharmacol 170:624-640.
12. Bhattacharya AAL, Shoblock J, Lord B, de Haes P, Drinkenburg W, Bouwknecht A, Ceusters M, Bonaventure P, Letavic M, and Lovenberg T (2014) Role of P2X7 ion channel in mood disorders: characterization of a P2X7 antagonist JNJ-42253432 in the rat brain, in Proceedings of the 29th CINP World Congress of Neuropsychopharmacology; 2014 June 22-26; Vancouver, BC, Canada. International College of Neuropsychopharmacology, Glasgow, UK
13. Burnstock G (2008) Purinergic signalling and disorders of the central nervous system. Nat Rev Drug Discov 7:575-590.
14. Burnstock G (2014) Physiopathological roles of p2x receptors in the central nervous system. Curr Med Chem DOI: 10.2174/0929867321666140706130415 [published ahead of print].
15. Burnstock G, Fredholm BB, and Verkhratsky A (2011a) Adenosine and ATP receptors in the brain. Curr Top Med Chem 11:973-1011.
16. Burnstock G, Krügel U, Abbracchio MP, and Illes P (2011b) Purinergic signalling: from normal behaviour to pathological brain function. Prog Neurobiol 95:229-274.
17. Catanzaro JM, Hueston CM, Deak MM, and Deak T (2014) The impact of the P2X7 receptor antagonist A-804598 on neuroimmune and behavioral consequences of stress. Behav Pharmacol 25:582-598.
18. Chessell IP, Hatcher JP, Bountra C, Michel AD, Hughes JP, Green P, Egerton J, Murfin M, Richardson J, and Peck WL, et al. (2005) Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 114:386-396.
19. Chrovian CC, Rech JC, Bhattacharya A, and Letavic MA (2014) P2X7 antagonists as potential therapeutic agents for the treatment of CNS disorders. Prog Med Chem 53:65-100.
20. Clark AK, Wodarski R, Guida F, Sasso O, and Malcangio M (2010) Cathepsin S release from primary cultured microglia is regulated by the P2X7 receptor. Glia 58:1710-1726.
21. Csölle C, Andó RD, Kittel Á, Gölöncsér F, Baranyi M, Soproni K, Zelena D, Haller J, Németh T, and Mócsai A, et al. (2013) The absence of P2X7 receptors (P2rx7) on non-haematopoietic cells leads to selective alteration in mood-related behaviour with dysregulated gene expression and stress reactivity in mice. Int J Neuropsychopharmacol 16:213-233.
22. Dantzer R (2004) Innate immunity at the forefront of psychoneuroimmunology. Brain Behav Immun 18:1-6.
23. Deak T, Arakawa H, Bekkedal MY, and Panksepp J (2009) Validation of a novel social investigation task that may dissociate social motivation from exploratory activity. Behav Brain Res 199:326-333.
24. Diaz-Hernandez JI, Gomez-Villafuertes R, León-Otegui M, Hontecillas-Prieto L, Del Puerto A, Trejo JL, Lucas JJ, Garrido JJ, Gualix J, and Miras-Portugal MT, et al. (2012) In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer's disease through GSK3β and secretases. Neurobiol Aging 33:1816-1828.
25. Donnelly-Roberts DL, Namovic MT, Surber B, Vaidyanathan SX, Perez-Medrano A, Wang Y, Carroll WA, and Jarvis MF (2009) [3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors. Neuropharmacology 56:223-229.
26. Engel T, Gomez-Villafuertes R, Tanaka K, Mesuret G, Sanz-Rodriguez A, Garcia-Huerta P, Miras-Portugal MT, Henshall DC, and Diaz-Hernandez M (2012) Seizure suppression and neuroprotection by targeting the purinergic P2X7 receptor during status epilepticus in mice. FASEB J 26:1616-1628.
27. Ficker C, Rozmer K, Kató E, Andó RD, Schumann L, Krügel U, Franke H, Sperlágh B, Riedel T, and Illes P (2014) Astrocyte-neuron interaction in the substantia gelatinosa of the spinal cord dorsal horn via P2X7 receptor-mediated release of glutamate and reactive oxygen species. Glia 62:1671-1686.
28. Hennessy MB, Deak T, and Schiml PA (2014) Sociality and sickness: have cytokines evolved to serve social functions beyond times of pathogen exposure? Brain Behav Immun 37:15-20.
29. Iwata M, Ota KT, and Duman RS (2013) The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. Brain Behav Immun 31:105-114.
30. Jobert M, Wilson FJ, Ruigt GS, Brunovsky M, Prichep LS, and Drinkenburg WH; IPEG Pharmaco-EEG Guidelines Committee (2012) Guidelines for the recording and evaluation of pharmaco-EEG data in man: the International Pharmaco-EEG Society (IPEG). Neuropsychobiology 66:201-220.
31. Keystone EC, Wang MM, Layton M, Hollis S, and McInnes IB; D1520C00001 Study Team (2012) Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis 71:1630-1635.
32. Khakh BS and North RA (2012) Neuromodulation by extracellular ATP and P2X receptors in the CNS. Neuron 76:51-69.
33. Kim SH and Chung JM (1992) An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50:355-363.
34. Klimesch W, Sauseng P, and Hanslmayr S (2007) EEG alpha oscillations: the inhibition-timing hypothesis. Brain Res Brain Res Rev 53:63-88.
35. McQuillin A, Bass NJ, Choudhury K, Puri V, Kosmin M, Lawrence J, Curtis D, and Gurling HM (2009) Case-control studies show that a non-conservative aminoacid change from a glutamine to arginine in the P2RX7 purinergic receptor protein is associated with both bipolar- and unipolar-affective disorders. Mol Psychiatry 14:614-620.
36. Mesuret G, Engel T, Hessel EV, Sanz-Rodriguez A, Jimenez-Pacheco A, Miras-Portugal MT, Diaz-Hernandez M, and Henshall DC (2014) P2X7 receptor inhibition interrupts the progression of seizures in immature rats and reduces hippocampal damage. CNS Neurosci Ther 20:556-564.
37. North RA and Jarvis MF (2013) P2X receptors as drug targets. Mol Pharmacol 83:759-769.
38. Roger S, Mei ZZ, Baldwin JM, Dong L, Bradley H, Baldwin SA, Surprenant A, and Jiang L-H (2010) Single nucleotide polymorphisms that were identified in affective mood disorders affect ATP-activated P2X7 receptor functions. J Psychiatr Res 44:347-355.
39. Sharp AJ, Polak PE, Simonini V, Lin SX, Richardson JC, Bongarzone ER, and Feinstein DL (2008) P2x7 deficiency suppresses development of experimental autoimmune encephalomyelitis. J Neuroinflammation 5:33.
40. Shiratori M, Tozaki-Saitoh H, Yoshitake M, Tsuda M, and Inoue K (2010) P2X7 receptor activation induces CXCL2 production in microglia through NFAT and PKC/MAPK pathways. J Neurochem 114:810-819.
41. Solle M, Labasi J, Perregaux DG, Stam E, Petrushova N, Koller BH, Griffiths RJ, and Gabel CA (2001) Altered cytokine production in mice lacking P2X(7) receptors. J Biol Chem 276:125-132.
42. Soronen P, Mantere O, Melartin T, Suominen K, Vuorilehto M, Rytsala H, Arvilommi P, Holma I, Holma M, and Jylha P, et al. (2011) P2RX7 gene is associated consistently with mood disorders and predicts clinical outcome in three clinical cohorts. Am J Med Genet B Neuropsychiatr Genet 156B:435-447.
43. Sperlagh B, Csolle C, Ando RD, Goloncser F, Kittel A, and Baranyi M (2012) The role of purinergic signaling in depressive disorders. Neuropsychopharmacol Hung 14:231-238.
44. Stock TC, Bloom BJ, Wei N, Ishaq S, Park W, Wang X, Gupta P, and Mebus CA (2012) Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol 39:720-727.
45. Stokes L, Fuller SJ, Sluyter R, Skarratt KK, Gu BJ, and Wiley JS (2010) Two haplotypes of the P2X(7) receptor containing the Ala-348 to Thr polymorphism exhibit a gain-of-function effect and enhanced interleukin-1beta secretion. FASEB J 24:2916-2927.
46. Varlinskaya EI, Truxell EM, and Spear LP (2013) Repeated restraint stress alters sensitivity to the social consequences of ethanol differentially in early and late adolescent rats. Pharmacol Biochem Behav 113:38-45.